HoldingsChannel.com
Aerie Pharmaceuticals insider buying image
The table below summarizes the most recent Aerie Pharmaceuticals insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Aerie Pharmaceuticals insider buys are important for investors to follow.
DateInsiderPriceAmount
9-9-2019
Insider Buy
Richard J. Rubino
Chief Financial Officer
$19.93
CAGR »
$100,447.20
5,040 shares
9-9-2019
Insider Buy
Vicente Anido Jr.
Chief Executive Officer
$19.01
CAGR »
$498,952.50
26,250 shares
9-5-2019
Insider Buy
Foresite Capital Management II, LLC
>10% Owner
$18.47
CAGR »
$2,140,890.00
115,900 shares
9-3-2019
Insider Buy
Foresite Capital Management II, LLC
>10% Owner
$21.00
CAGR »
$1,574,741.00
75,000 shares
8-23-2019
Insider Buy
Foresite Capital Management II, LLC
>10% Owner
$23.45
CAGR »
$1,082,449.25
46,153 shares
8-20-2019
Insider Buy
Foresite Capital Management II, LLC
>10% Owner
$23.88
CAGR »
$3,673,288.98
153,847 shares
8-14-2019
Insider Buy
Foresite Capital Management II, LLC
>10% Owner
$24.73
CAGR »
$13,341,170.45
539,555 shares
11-16-2018
Insider Buy
Gerald D. Cagle
Director
$41.75
CAGR »
$83,493.20
2,000 shares
5-25-2018
Insider Buy
Gerald D. Cagle
Director
$49.45
CAGR »
$49,450.00
1,000 shares
5-21-2018
Insider Buy
Gerald D. Cagle
Director
$50.24
CAGR »
$50,245.00
1,000 shares
5-9-2017
Insider Buy
Gerald D. Cagle
Director
$39.90
CAGR »
$39,900.00
1,000 shares
4-19-2017
Insider Buy
Gerald D. Cagle
Director
$41.70
CAGR »
$83,400.00
2,000 shares
8-28-2015
Insider Buy
Gerald D. Cagle
Director
$18.24
CAGR »
$84,765.64
4,646 shares
10-25-2013
Insider Buy
Clarus Lifesciences II, L.P.
>10% Owner
$10.00
CAGR »
$3,210,000.00
321,000 shares
5-16-2014
Insider Buy
Gerald D. Cagle
Director
$15.07
CAGR »
$27,939.78
1,854 shares
10-30-2013
Insider Buy
ACP IV, L.P.
>10% Owner
$10.00
CAGR »
$1,100,000.00
110,000 shares
10-30-2013
Insider Buy
Richard J. Rubino
Chief Financial Officer
$10.00
CAGR »
$100,000.00
10,000 shares
10-30-2013
Insider Buy
Vicente Anido Jr.
Chief Executive Officer
$10.00
CAGR »
$280,000.00
28,000 shares
10-30-2013
Insider Buy
Thomas A. Mitro
President and COO
$10.00
CAGR »
$50,000.00
5,000 shares
10-30-2013
Insider Buy
Brian Levy
Chief Medical Officer
$10.00
CAGR »
$60,000.00
6,000 shares
10-25-2013
Insider Buy
Anand Mehra
Director and >10% Owner
$10.00
CAGR »
$2,850,000.00
285,000 shares

Also See: Institutional Holders of AERI
Also See: SEC filings

AERI Performance Since Insider Purchase
Below we present the annualized performance delivered by Aerie Pharmaceuticals stock since 9-9-2019 (the date of the most recent insider purchase). The performance of the investment from the time Aerie Pharmaceuticals insider buying occurred is the ultimate test of whether insiders were right about AERI being a good buy.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 09/10/2019
End date: 11/21/2022
Start price/share: $22.16
End price/share: $15.25
Dividends collected/share: $0.00
Total return: -31.18%
Average Annual Total Return: -11.02%
Starting investment: $10,000.00
Ending investment: $6,882.33
Years: 3.20

Aerie Pharmaceuticals Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Aerie Pharmaceuticals insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding AERI

Quotes delayed 20 minutes

Email EnvelopeFree AERI Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Aerie Pharmaceuticals Insider Buying | www.HoldingsChannel.com

Copyright © 2013 - 2024, All Rights Reserved Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.